Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 69

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 69
---
510 |     | $        | 999,992 |     |                             | 25,510 |

| (1) | Daniel                                                                                                                             
 Corey served as the Chief Technology Officer and a member of the board of directors of the Company from February 2024 to September 
 2024, and previously served as Chief Executive Officer, Chief Scientific Officer, and a member of the board of directors of Legacy 
 CERo until the closing of the Business Combination in February 2024.                                                               |

| (2) | Brian                                                                                          
 G. Atwood served as Chairman and Chief Executive Officer of the Company from February 2024     
 to September 2024, and previously served as Chairman of PBAX until the closing of the Business 
 Combination in February 2024. Mr. Atwood is currently a member of the board of directors       
 of the Company and serves as a trustee of Atwood-Edminster Trust dtd 4-2-2000. GVN, LLC,       
 is a limited liability company of which the sole member is the Atwood-Edminster Trust dtd      
 4-2-2000, and of which Brian G. Atwood and Lynne H. Edminster are the managers.                |

| (3) | Chris                                                                                           
 Ehrlich has served as the Chairman and Chief Executive Officer of the Company since December    
 2024, and previously served as (i) interim Chairman and Chief Executive Officer of the Company  
 from October 2024 to November 2024, (ii) Vice Chairman of the board of directors of the Company 
 from February 2024 to September 2024, and (iii) the Chief Executive Officer of PBAX until       
 the closing of the Business Combination in February 2024.                                       |

On April 22, 2025, pursuant
to the Fourth Securities Purchase Agreement, the Company issued and sold, and the investors purchased, in a private placement (the “Fourth
PIPE Financing”), 6,250 shares of the Series D Preferred Stock to investors in exchange for the receipt of 1,000,279 shares of the
Stella Series D Preferred Stock in lieu of cash, in which a portion of the Stella Series D Preferred Stock was owned by a related party
investor. The investor is a majority shareholder of Stella Diagnostics, Inc. and has representation on the board of directors thereof.

During the six months ended June 30, 2025 and for the period from February 14, 2024 to